ERBB2 and breast carcinoma: In addition to TNBC, sacituzumab govitecan has shown encouraging results when treating hormone receptor-positive/HER2-negative metastatic luminal breast cancer that had progressed after endocrine-based therapy and at least one prior chemotherapy; achieving an ORR of 31.5% [4].